Toll-like receptors in inflammation, infection and cancer

International Immunopharmacology

Volumn 7, Issue 10, 2007, Pages 1271-1285

  Chen, Keqiang ^a,b   Huang, Jian ^a   Gong, Wanghua ^c   Iribarren, Pablo ^d   Dunlop, Nancy M ^a   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Cancer; Infection; Inflammation; Ligands; Signaling; Toll like receptors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DEFENSIN; EOSINOPHIL PROTEIN X; FIBRINOGEN; FLAGELLIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; REACTIVE OXYGEN METABOLITE; SURFACTANT PROTEIN A; TOLL LIKE RECEPTOR; VIRUS RNA;

ACNE VULGARIS; ALZHEIMER DISEASE; ASTHMA; CANCER; CANCER GROWTH; CHLAMYDOPHILA PNEUMONIAE; CRYPTOCOCCUS NEOFORMANS; ENTERITIS; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; INFLUENZA VIRUS A; KIDNEY DISEASE; LEGIONELLA PNEUMOPHILA; LEPROSY; LYME DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW;

ANIMALS; BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; LIGANDS; NEOPLASMS; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 34547231172     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.05.016     Document Type: Review

References (136)

1. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int Immunol 17 (2005) 1-14
2. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5 (2005) 446-458
3. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
4. Takeda K., and Akira S. TLR signaling pathways. Semin Immunol 16 (2004) 3-9
5. Cook D.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975-979
6. Chaudhuri N., Dower S.K., Whyte M.K., and Sabroe I. Toll-like receptors and chronic lung disease. Clin Sci (Lond) 109 (2005) 125-133
7. Eriksson U., Ricci R., Hunziker L., Kurrer M.O., Oudit G.Y., Watts T.H., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9 (2003) 1484-1490
8. Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E.H., et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem 281 (2006) 3651-3659
9. Cui Y.H., Le Y., Gong W., Proost P., Van Damme J., Murphy W.J., et al. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol 168 (2002) 434-442
10. Iribarren P., Chen K., Hu J., Gong W., Cho E.H., Lockett S., et al. CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2. FASEB J 19 (2005) 2032-2034
11. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526
12. Sabroe I., Read R.C., Whyte M.K., Dockrell D.H., Vogel S.N., and Dower S.K. Toll-like receptors in health and disease: complex questions remain. J Immunol 171 (2003) 1630-1635
13. Hirschfeld M., Ma Y., Weis J.H., Vogel S.N., and Weis J.J. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165 (2000) 618-622
14. Finberg R.W., Re F., Popova L., Golenbock D.T., and Kurt-Jones E.A. Cell activation by Toll-like receptors: role of LBP and CD14. J Endotoxin Res 10 (2004) 413-418
15. Perera P.Y., Mayadas T.N., Takeuchi O., Akira S., Zaks-Zilberman M., Goyert S.M., et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 166 (2001) 574-581
16. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100 (2003) 1966-1971
17. Kurt-Jones E.A., Popova L., Kwinn L., Kwinn L., Haynes L.M., Jones L.P., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 (2000) 398-401
18. Knapp S., Wieland C.W., van 't Veer C., Takeuchi O., Akira S., Florquin S., et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172 (2004) 3132-3138
19. Means T.K., Jones B.W., Schromm A.B., Shurtleff B.A., Smith J.A., Keane J., et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 166 (2001) 4074-4082
20. Martin M., Katz J., Vogel S.N., and Michalek S.M. Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. J Immunol 167 (2001) 5278-5285
21. Katz J., Zhang P., Martin M., Vogel S.N., and Michalek S.M. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun 74 (2006) 2809-2816
22. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
23. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
24. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
25. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33 (2003) 2987-2997
26. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27 (2002) 571-577
27. Hochrein H., Schlatter B., O'Keeffe M., Wagner C., Schmitz F., Schiemann M., et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and- independent pathways. Proc Natl Acad Sci U S A 101 (2004) 11416-11421
28. Lund J., Sato A., Akira S., Medzhitov R., and Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198 (2003) 513-520
29. Bellocchio S., Moretti S., Perruccio K., Fallarino F., Bozza S., Montagnoli C., et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 173 (2004) 7406-7415
30. Tabeta K., Georgel P., Janssen E., Du X., Hoebe K., Crozat K., et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 101 (2004) 3516-3521
31. Krug A., French A.R., Barchet W., Fischer J.A., Dzionek A., Pingel J.T., et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21 (2004) 107-119
32. Yarovinsky F., Zhang D., Andersen J.F., et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308 (2005) 1626-1629
33. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298 (2002) 1025-1029
34. Frantz S., Kelly R.A., and Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 276 (2001) 5197-5203
35. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279 (2004) 7370-7377
36. Guillot L., Balloy V., McCormack F.X., Golenbock D.T., Chignard M., and Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 168 (2002) 5989-5992
37. Smiley S.T., King J.A., and Hancock W.W. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167 (2001) 2887-2894
38. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276 (2001) 10229-10233
39. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195 (2002) 99-111
40. Oppenheim J.J., and Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17 (2005) 359-365
41. Tsan M.F., and Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 76 (2004) 514-519
42. Kawai T., and Akira S. TLR signaling. Semin Immunol 19 (2007) 24-32
43. Olson J.K., and Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173 (2004) 3916-3924
44. Bsibsi M., Ravid R., Gveric D., and van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61 (2002) 1013-1021
45. McKimmie C.S., and Fazakerley J.K. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J Neuroimmunol 169 (2005) 116-125
46. Le Y., Gong W., Tiffany H.L., Tumanov A., Nedospasov S., Shen W., et al. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 21 (2001) RC123
47. DiCarlo G., Wilcock D., Henderson D., Gordon M., and Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 22 (2001) 1007-1012
48. Herber D.L., Roth L.M., Wilson D., Wilson N., Mason J.E., Morgan D., et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 190 (2004) 245-253
49. Jack C., Ruffini F., Bar-Or A., and Antel J.P. Microglia and multiple sclerosis. J Neurosci Res 81 (2005) 363-373
50. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 116 (2006) 456-464
51. Sorensen T.L., Trebst C., Kivisakk P., Klaege K.L., Majmudar A., Ravid R., et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 127 (2002) 59-68
52. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280 (2005) 5571-5580
53. Soong G., Reddy B., Sokol S., Adamo R., and Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 113 (2004) 1482-1489
54. Sukkar M.B., Xie S., Khorasani N.M., Kon O.M., Stanbridge R., Issa R., et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 118 (2006) 641-648
55. Sato M., Sano H., Iwaki D., Kudo K., Konishi M., Takahashi H., et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol 171 (2003) 417-425
56. Morris G.E., Whyte M.K., Martin G.F., Jose P.J., Dower S.K., and Sabroe I. Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med 171 (2005) 814-822
57. Prince L.R., Allen L., Jones E.C., Hellewell P.G., Dower S.K., Whyte M.K., et al. The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol 165 (2004) 1819-1826
58. Eisenbarth S.C., Piggott D.A., Huleatt J.W., Visintin I., Herrick C.A., and Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 196 (2002) 1645-1651
59. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 (2003) 403-411
60. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
61. Constant S.L., Brogdon J.L., Piggott D.A., Herrick C.A., Visintin I., Ruddle N.H., et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest 110 (2002) 1441-1448
62. Schilling D., Thomas K., Nixdorff K., Vogel S.N., and Fenton M.J. Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages. J Immunol 169 (2002) 5874-5880
63. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 174 (2005) 7558-7563
64. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., and Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Droisophila adults. Cell 86 (1996) 973-983
65. Eder W., Klimecki W., Yu L., von Mutius E., Riedler J., Braun-Fahrlander C., et al. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 113 (2004) 482-488
66. Krieg A.M. The role of CpG motifs in innate immunity. Curr Opin Immunol 12 (2000) 35-43
67. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., and Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 162 (1999) 6284-6293
68. Wild J.S., Choudhury B.K., and Sur S. CpG DNA modulation of allergic asthma. Isr Med Assoc J 2 (2000) 13-15 Suppl
69. Lorenz E., Jones M., Wohlford-Lenane C., Meyer N., Frees K.L., Arbour N.C., et al. Genes other than TLR4 are involved in the response to inhaled LPS. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1106-L1114
70. Basu S., and Fenton M.J. Toll-like receptors: function and roles in lung disease. Am J Physiol Lung Cell Mol Physiol 286 (2004) L887-L892
71. Shapiro S.D. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) S29-S32
72. Shapiro S.D., Campbell E.J., Kobayashi D.K., and Welgus H.G. Dexamethasone selectively modulates basal and lipopolysaccharide-induced metalloproteinase and tissue inhibitor of metalloproteinase production by human alveolar macrophages. J Immunol 146 (1991) 2724-2729
73. Rodriguez N., Wantia N., Fend F., Durr S., Wagner H., and Miethke T. Differential involvement of TLR2 and TLR4 in host survival during pulmonary infection with Chlamydia pneumoniae. Eur J Immunol 36 (2006) 1145-1155
74. Tjarnlund A., Guirado E., Julian E., Cardona P.J., and Fernandez C. Determinant role for Toll-like receptor signalling in acute mycobacterial infection in the respiratory tract. Microbes Infect 8 (2006) 1790-1800
75. Drennan M.B., Nicolle D., Quesniaux V.J., Jacobs M., Allie N., Mpagi J., et al. Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. Am J Pathol 164 (2004) 49-57
76. Bafica A., Scanga C.A., Feng C.G., Leifer C., Cheever A., and Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 202 (2005) 1715-1724
77. Archer K.A., and Roy C.R. MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires' disease. Infect Immun 74 (2006) 3325-3333
78. Yauch L.E., Mansour M.K., Shoham S., Rottman J.B., and Levitz S.M. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun 72 (2004) 5373-5382
79. Le Goffic R., Balloy V., Lagranderie M., Alexopoulou L., Escriou N., Flavell R., et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2 (2006) e53
80. Fukui T., Nishio A., Okazaki K., Uza N., Ueno S., Kido M., et al. Gastric mucosal hyperplasia via upregulation of gastrin induced by persistent activation of gastric innate immunity in major histocompatibility complex class II deficient mice. Gut 55 (2006) 607-615
81. Ishihara S., Rumi M.A., Kadowaki Y., Ortega-Cava C.F., Yuki T., Yoshino N., et al. Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol 173 (2004) 1406-1416
82. Otte J.M., Rosenberg I.M., and Podolsky D.K. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124 (2003) 1866-1878
83. Gewirtz A.T., Simon Jr. P.O., Schmitt C.K., Taylor L.J., Hagedorn C.H., O'Brien A.D., et al. Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response. J Clin Invest 107 (2001) 99-109
84. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000) 7010-7017
85. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
86. Torok H.P., Glas J., Tonenchi L., Mussack T., and Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 112 (2004) 85-91
87. Singh J.C., Cruickshank S.M., Newton D.J., Wakenshaw L., Graham A., Lan J., et al. Toll-like receptor-mediated responses of primary intestinal epithelial cells during the development of colitis. Am J Physiol Gastrointest Liver Physiol 288 (2005) G514-G524
88. Sitaraman S.V., Klapproth J.M., Moore III D.A., Landers C., Targan S., Williams I.R., et al. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 288 (2005) G403-G406
89. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113 (2004) 1296-1306
90. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
91. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
92. Netea M.G., Kullberg B.J., de Jong D.J., Franke B., Sprong T., Naber T.H., et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 34 (2004) 2052-2059
93. Watanabe T., Kitani A., Murray P.J., and Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5 (2004) 800-808
94. Backhed F., Rokbi B., Torstensson E., Zhao Y., Nilsson C., Seguin D., et al. Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like receptor 4. J Infect Dis 187 (2003) 829-836
95. Mandell L., Moran A.P., Cocchiarella A., Houghton J., Taylor N., Fox J.G., et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 72 (2004) 6446-6454
96. Schmausser B., Andrulis M., Endrich S., Muller-Hermelink H.K., and Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295 (2005) 179-185
97. Leveque G., Forgetta V., Morroll S., Smith A.L., Bumstead N., Barrow P., et al. Allelic variation in TLR4 is linked to susceptibility to Salmonella enterica serovar Typhimurium infection in chickens. Infect Immun 71 (2003) 1116-1124
98. Lembo A., Kalis C., Kirschning C.J., Mitolo V., Jirillo E., Wagner H., et al. Differential contribution of Toll-like receptors 4 and 2 to the cytokine response to Salmonella enterica serovar Typhimurium and Staphylococcus aureus in mice. Infect Immun 71 (2003) 6058-6062
99. Khan M.A., Kang J., and Steiner T.S. Enteroaggregative Escherichia coli flagellin-induced interleukin-8 secretion requires Toll-like receptor 5-dependent p38 MAP kinase activation. Immunology 112 (2004) 651-660
100. Aliprantis A.O., Weiss D.S., Radolf J.D., and Zychlinsky A. Release of Toll-like receptor-2-activating bacterial lipoproteins in Shigella flexneri culture supernatants. Infect Immun 69 (2001) 6248-6255
101. Maldonado-Bernal C., Kirschning C.J., Rosenstein Y., Rocha L.M., Rios-Sarabia N., Espinosa-Cantellano M., et al. The innate immune response to Entamoeba histolytica lipopeptidophosphoglycan is mediated by toll-like receptors 2 and 4. Parasite Immunol 27 (2005) 127-137
102. Tsuboi N., Yoshikai Y., Matsuo S., Kikuchi T., Iwami K., Nagai Y., et al. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol 169 (2002) 2026-2033
103. Lehmann J., Retz M., Harder J., Krams M., Kellner U., Hartmann J., et al. Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect Dis 2 (2002) 20
104. Cunningham P.N., Wang Y., Guo R., He G., and Quigg R.J. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 172 (2004) 2629-2635
105. Nitschke M., Wiehl S., Baer P.C., and Kreft B. Bactericidal activity of renal tubular cells: the putative role of human beta-defensins. Exp Nephrol 10 (2002) 332-337
106. Anders H.J., Banas B., and Schlondorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15 (2004) 854-867
107. Baker B.S., Ovigne J.M., Powles A.V., Corcoran S., and Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 148 (2003) 670-679
108. Pivarcsi A., Bodai L., Rethi B., Kenderessy-Szabo A., Koreck A., Szell M., et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 15 (2003) 721-730
109. Mempel M., Voelcker V., Kollisch G., Plank C., Rad R., Gerhard M., et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121 (2003) 1389-1396
110. Krutzik S.R., Ochoa M.T., Sieling P.A., Uematsu S., Ng Y.W., Legaspi A., et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9 (2003) 525-532
111. Kim J., Ochoa M.T., Krutzik S.R., Takeuchi O., Uematsu S., Legaspi A.J., et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169 (2002) 1535-1541
112. Curry J.L., Qin J.Z., Bonish B., Carrick R., Bacon P., Panella J., et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 127 (2003) 178-186
113. McInturff J.E., Modlin R.L., and Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 125 (2005) 1-8
114. Bulut Y., Faure E., Thomas L., Equils O., and Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 167 (2001) 987-994
115. Alexopoulou L., Thomas V., Schnare M., Lobet Y., Anguita J., Schoen R.T., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8 (2002) 878-884
116. Killeen S.D., Wang J.H., Andrews E.J., and Redmond H.P. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?. Br J Cancer 95 (2006) 247-252
117. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., and Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
118. Chang Y.J., Wu M.S., Lin J.T., Sheu B.S., Muta T., Inoue H., et al. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol 66 (2004) 1465-1477
119. Harmey J.H., Bucana C.D., Lu W., Byrne A.M., McDonnell S., Lynch C., et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101 (2002) 415-422
120. Wang J.H., Manning B.J., Wu Q.D., Blankson S., Bouchier-Hayes D., and Redmond H.P. Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 170 (2003) 795-804
121. Luo J.L., Maeda S., Hsu L.C., Yagita H., and Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297-305
122. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65 (2005) 5009-5014
123. Cheadle E.J., and Jackson A.M. Bugs as drugs for cancer. Immunology 107 (2002) 10-19
124. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68 (2000) 6883-6890
125. Okamoto M., Oshikawa T., Tano T., Ohe G., FuruichiV S., Nishikawa H., et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95 (2003) 316-326
126. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 64 (2004) 5850-5860
127. Jahrsdorfer B., Muhlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11 (2005) 1490-1499
128. Urosevic M., Dummer R., Conrad C., Beyeler M., Laine E., Burg G., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97 (2005) 1143-1153
129. El Andaloussi A., Sonabend A.M., Han Y., and Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54 (2006) 526-535
130. Spaner D.E., and Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21 (2007) 53-60
131. Hopkins P.A., and Sriskandan S. Toll-like receptors: to immunity and beyond. Clin Exp Immunol 140 (2005) 395-407
132. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 171 (2003) 4984-4989
133. Koski G.K., and Czerniecki B.J. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res 11 (2005) 7-11
134. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 176 (2006) 6624-6630
135. Salaun B., Coste I., Rissoan M.C., Lebecque S.J., and Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176 (2006) 4894-4901
136. Szczepanski M., Stelmachowska M., Stryczynski L., Golusinski W., Samara H., Mozer-Lisewska I., et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 264 (2007) 525-530